Education
About Us
Working with TipRanks
Follow Us
Transgene SA (GB:0OCQ)
LSE:0OCQ
Total Valuation
Transgene has a market cap or net worth of €104.06M. The enterprise value is €163.02M.
Market Cap€104.06M
Enterprise Value€163.02M
Share Statistics
Transgene has 132,735,080 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding132,735,080
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Transgene’s return on equity (ROE) is -2.23 and return on invested capital (ROIC) is -107.38%.
Return on Equity (ROE)-2.23
Return on Assets (ROA)-0.81
Return on Invested Capital (ROIC)-107.38%
Return on Capital Employed (ROCE)-1.26
Revenue Per Employee2.13K
Profits Per Employee-235.91K
Employee Count144
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Transgene is -2.34. Transgene’s PEG ratio is -0.10.
PE Ratio-2.34
PS Ratio0.00
PB Ratio4.36
Price to Fair Value5.22
Price to FCF-7.55
Price to Operating Cash Flow-8.13
PEG Ratio-0.10
Income Statement
In the last 12 months, Transgene had revenue of 307.00K and earned -33.97M in profits. Earnings per share was -0.34.
Revenue307.00K
Gross Profit307.00K
Operating Income-35.66M
Pretax Income-40.02M
Net Income-33.97M
EBITDA-26.65M
Earnings Per Share (EPS)-0.34
Cash Flow
In the last 12 months, operating cash flow was -23.84M and capital expenditures -3.07M, giving a free cash flow of -26.91M billion.
Operating Cash Flow-23.84M
Free Cash Flow-26.91M
Free Cash Flow per Share-0.20
Dividends & Yields
Transgene pays an annual dividend of €0.285, resulting in a dividend yield of ―
Dividend Per Share€0.285
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.44
52-Week Price Change-22.64%
50-Day Moving Average0.77
200-Day Moving Average0.79
Relative Strength Index (RSI)47.09
Average Volume (3m)2.01K
Important Dates
Transgene upcoming earnings date is Sep 16, 2025, During Market Hours (Confirmed).
Last Earnings DateApr 24, 2025
Next Earnings DateSep 16, 2025
Ex-Dividend DateMar 15, 2022
Financial Position
Transgene as a current ratio of 1.48, with Debt / Equity ratio of 6.47%
Current Ratio1.48
Quick Ratio1.48
Debt to Market Cap0.00
Net Debt to EBITDA0.63
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Transgene has paid -6.05M in taxes.
Income Tax-6.05M
Effective Tax Rate0.15
Enterprise Valuation
Transgene EV to EBITDA ratio is -2.35, with an EV/FCF ratio of -2.35.
EV to Sales204.12
EV to EBITDA-2.35
EV to Free Cash Flow-2.35
EV to Operating Cash Flow-2.66
Balance Sheet
Transgene has €16.67M in cash and marketable securities with €0.00 in debt, giving a net cash position of -€16.67M billion.
Cash & Marketable Securities€16.67M
Total Debt€0.00
Net Cash-€16.67M
Net Cash Per Share-€0.13
Tangible Book Value Per Share€0.13
Margins
Gross margin is -929.05%, with operating margin of -11614.98%, and net profit margin of -11065.47%.
Gross Margin-929.05%
Operating Margin-11614.98%
Pretax Margin-13034.85%
Net Profit Margin-11065.47%
EBITDA Margin-8681.37%
EBIT Margin-9098.63%
Analyst Forecast
The average price target for Transgene is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―